The nation of Zimbabwe has turned down a major American health deal valued at 367 million US dollars (£272m) over five years over the United States' insistence on sensitive data.
This move came to light after a internal memorandum dated December was disclosed, which showed President Emmerson Mnangagwa believed the deal was "unbalanced".
An official spokesperson has since stated that the US was requesting health data for scientific study and commercial purposes but was unwilling to guarantee the benefits from any future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for further talks to secure a deal acceptable to all parties so the nation's vital HIV programme can be sustained.
Wider Background
Zimbabwe's decision follows a comparable case in neighbouring Kenya, where a court blocked a related health funding agreement following concerns were raised about the security of Kenyans' health data.
After returning to the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the US government, but Trump argued its expenditure was "inefficient" and his government was seeking direct bilateral deals to enhance transparency and responsibility.
As per reports, 16 African countries have to date agreed to these new agreements, representing over $18.3bn of fresh investment.
Specifics of the Declined Agreement
This assistance for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving antiretroviral therapy through American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana maintained the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information over an extended period, without any corresponding promise of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"In essence, our nation would provide the raw materials for medical research with no certainty that the end products would be available to our population should a new pandemic arise."
National Interest and International Frameworks
He also pointed out that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were disrupting structures previously established via the global health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing system designed to deal with potential pandemics.
"This mechanism is intended to guarantee that when a country provides its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to develop them."
These objections over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage continued discussions with our US partners on how future collaboration might be designed in a manner that respects the sovereignty and interests of each country."
Medical Community Reaction
A leading public health body said it recognised the official position, but urged that talks must proceed since much of the country's HIV programmes were funded by international support.
"If specific concerns exist, such as those relating to information security or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," it added.
The halted deal emphasises the complex debate between receiving crucial foreign assistance and protecting national sovereignty in an increasingly data-driven world.